A
Advicenne
Develops and markets pediatric drugs for the treatment of neurological diseases of the central nervous system and nephrological disorders
About Advicenne
Advicenne is a pharmaceutical company focused on developing and commercializing innovative treatments for rare renal diseases. The company serves both children and adults, addressing high unmet medical needs in the healthcare market. Advicenne operates primarily in Europe and the United States, with its headquarters in Paris. The company's business model revolves around the reformulation and delivery of groundbreaking medicines, leveraging its expertise to create products that improve daily health and life. Advicenne generates revenue through the sale of its approved medications, such as the combination of Potassium citrate and Potassium bicarbonate, which received approval from the European Medicine Agency and MHRA in 2021. Listed on Euronext Growth (Euronext ALDVI) since 2022, Advicenne continues to expand its portfolio and market reach. Keywords: rare renal diseases, innovative treatments, pharmaceutical, reformulation, drug delivery, children and adults, high unmet medical need, quality of life, European Medicine Agency, Euronext Growth.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Paris, France
- Listing
- IPO 2017
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 69.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Horizon Europe, participations bpifrance, observatoire industrial tech
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jun 2026 | $4.2M | — | Cemag Invest · L1 Capital | ↗ |
| POST IPO EQUITY✓Other financing | Jul 2025 | $2.9M | — | Friedland Gestion · Marker Wizards · Treecap · Maitice Gestion | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Advicenne is 1.1K monthly website visits, up 0% over the last three months. Advicenne's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later9 investors entered at this stage
iXO Private Equity
IRDI Gestion
European Investment Bank
Friedland Gestion
Marker Wizards
Treecap
Maitice Gestion
Cemag Invest- LCL1 Capital
Other known investors2 additional known investors
Crealia
Femmes Business Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Advicenne on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advicenne’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.